Drugplain

Plegridy

peginterferon beta-1a · KIT · Biogen Inc.

No Recall HistoryCurrently in Shortage
Plain English

Plegridy is a prescription medication given by injection under the skin to treat relapsing-remitting multiple sclerosis. It belongs to a class of drugs called interferon beta, which helps reduce the frequency of relapses in MS.

Key Facts

Brand Name
Plegridy
Generic Name
peginterferon beta-1a
NDC Code (Product)
64406-016
Manufacturer
Biogen Inc.
Dosage Form
KIT
Route
SUBCUTANEOUS
Marketing Status
Application #
BLA125499
Drug Class
Interferon beta [EPC]
Marketing Start
08/15/2014

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

influenza like illness1,459 reports
injection site erythema1,058 reports
multiple sclerosis relapse969 reports
fatigue710 reports
headache612 reports
pain603 reports
injection site reaction578 reports
device malfunction571 reports
multiple sclerosis558 reports
pyrexia518 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

1 INDICATIONS AND USAGE PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PLEGRIDY is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 )

Dosage & Administration

2 DOSAGE AND ADMINISTRATION For subcutaneous or intramuscular use only ( 2.1 ) Recommended dose: 125 micrograms every 14 days ( 2.1 ) PLEGRIDY dose should be titrated, starting with 63 micrograms on day 1, 94 micrograms on day 15, and 125 micrograms (full dose) on day 29 ( 2.1 ) A healthcare professional should train patients in the proper technique for self-administering subcutaneous injections using the prefilled pen or syringe or intramuscular injections using the prefilled syringe ( 2.2 ) Analgesics and/or antipyretics on treatment days may help ameliorate flu-like symptoms ( 2.3 ) 2.1 Dosing Information PLEGRIDY may only be administered subcutaneously (SC) or intramuscularly (IM). Recommended Maintenance Dosage After initial titration (see Table 1 and Table 2 ), the recommended dosage of PLEGRIDY is 125 micrograms injected every 14 days. For subcutaneous injection: Patients may rotate injection sites between the abdomen, back of the upper arm, or thigh. For intramuscular injection: Patients may rotate injection sites between the left and right thighs. Treatment Initiation Dose titration at the initiation of treatment may help to ameliorate flu-like symptoms that can occur at t

Contraindications

4 CONTRAINDICATIONS PLEGRIDY is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other component of PLEGRIDY [see Warnings and Precautions ( 5.3 )] . History of hypersensitivity to natural or recombinant interferon beta or peginterferon, or any other component of PLEGRIDY ( 4 )

Adverse Reactions

6 ADVERSE REACTIONS The following serious adverse reactions are discussed in more detail in other sections of labeling: Hepatic Injury [see Warnings and Precautions ( 5.1 )] Depression and Suicide [see Warnings and Precautions ( 5.2 )] Anaphylaxis and Other Allergic Reactions [see Warnings and Precautions ( 5.3 )] Injection Site Reactions Including Necrosis [see Warnings and Precautions ( 5.4 )] Congestive Heart Failure [see Warnings and Precautions (Section 5.5 )] Decreased Peripheral Blood Counts [see Warnings and Precautions ( 5.6 )] Thrombotic Microangiopathy [see Warnings and Precautions ( 5.7 )] Pulmonary Arterial Hypertension [see Warnings and Precautions ( 5.8 )] Autoimmune Disorders [see Warnings and Precautions ( 5.9 )] Seizures [see Warnings and Precautions ( 5.10 )] The most common adverse reactions in clinical trials of subcutaneous PLEGRIDY (incidence ≥10% and at least 2% more frequent on PLEGRIDY than on placebo) were injection site erythema, influenza-like illness, pyrexia, headache, myalgia, chills, injection site pain, asthenia, injection site pruritus, and arthralgia ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Biogen at 1-800-456-2255 or FDA at 1-800-F

Frequently Asked Questions

What is Plegridy used for?

Plegridy is a prescription medication given by injection under the skin to treat relapsing-remitting multiple sclerosis. It belongs to a class of drugs called interferon beta, which helps reduce the frequency of relapses in MS.

Is Plegridy a controlled substance?

Plegridy is not classified as a controlled substance by the DEA.

What is the generic name for Plegridy?

The generic name for Plegridy is peginterferon beta-1a. There are 2 other brand versions of peginterferon beta-1a.

What is the NDC code for Plegridy ?

The NDC (National Drug Code) for Plegridy is 64406-016, listed by Biogen Inc..

Product NDC

64406-016

Package NDC

64406-016-01

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)